Work

AIR – an open-label, 36-week, clinical trial of buloxibutid – investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF

Year: 2024

Type: conference-abstract

DOI: 10.1183/13993003.congress-2024.oa2859

Authors: Cecilia Ganslandt, Philip Molyneaux, Anand Devaraj, Bertil Lindmark, Johan Raud, Göran Tornling, Thomas Bengtsson, Toby M. Maher

Institutions: Vicore Pharma (Sweden), Imperial College London, Karolinska Institutet, University of Southern California

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404103999

Cites:

Cited by: 3

Related to: 10